You just read:

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

News provided by

TapImmune Inc.

Nov 07, 2014, 10:54 ET